Cyclopentenone prostaglandin-induced unfolding and aggregation of the Parkinson disease-associated UCH-L1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 15, 2010, Pages 6835-6840

  Koharudin, Leonardus M I ^a   Liu, Hao ^a,b   Di Maio, Roberto ^a   Kodali, Ravindra B ^a   Graham, Steven H ^a,b   Gronenborn, Angela M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Neurodegeneration; NMR; Oxidative damage; Protein modification; Ubiquitin

Indexed keywords

CYCLOPENTENONE DERIVATIVE; CYSTEINE; ELECTROPHILE; PROSTAGLANDIN; UBIQUITIN CARBOXYL TERMINAL HYDROLASE L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONJUGATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTROSPRAY MASS SPECTROMETRY; EMBRYO; ENZYME MODIFICATION; GENE MUTATION; IMMUNOHISTOCHEMISTRY; NERVE DEGENERATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN MODIFICATION; PROTEIN PURIFICATION; RAT;

ANIMALS; CYCLOPENTANES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICE; MUTATION; PARKINSON DISEASE; PROSTAGLANDIN D2; PROTEIN DENATURATION; RATS; RATS, SPRAGUE-DAWLEY; UBIQUITIN THIOLESTERASE;

EID: 77951069130     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1002295107     Document Type: Article

References (39)

1. Walsh CT, Garneau-Tsodikova S, Gatto GJ, Jr (2005) Protein posttranslational modifications: The chemistry of proteome diversifications. Angew Chem Int Ed Engl 44:7342-7372.
2. Boutaud O, Andreasson KI, Zagol-Ikapitte I, Oates JA (2005) Cyclooxygenase-dependent lipid-modification of brain proteins. Brain Pathol 15:139-142.
3. Kondo M, et al. (2001) Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J Biol Chem 276:12076-12083.
4. Gayarre J, et al. (2007) Modification of proteins by cyclopentenone prostaglandins is differentially modulated by GSH in vitro. Ann NY Acad Sci 1096:78-85.
5. Ishii T, Uchida K (2004) Induction of reversible cysteine-targeted protein oxidation by an endogenous electrophile 15-deoxy-delta12,14- prostaglandin J2. Chem Res Toxicol 17:1313-1322.
6. Sultana R, PerluigiM, Butterfield DA (2006) Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: Insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Sign 8:2021-2037.
7. Wilson PO, et al. (1988) The immunolocalization of protein gene product 95 using rabbit polyclonal and mouse monoclonal antibodies. Br J Exp Pathol 69:91-104.
8. Wilkinson KD, et al. (1989) The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246:670-673.
9. Das C, et al. (2006) Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1. Proc Natl Acad Sci USA 103:4675-4680.
10. Leroy E, et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395:451-452.
11. Maraganore DM, et al. (1999) Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 53:1858-1860.
12. Choi J, et al. (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 279:13256-13264.
13. Nishikawa K, et al. (2003) Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun 304:176-183.
14. Kabuta T, et al. (2008) Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1. Hum Mol Genet 17:1482-1496.
15. Li Z, et al. (2004) Delta12-Prostaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and elicits ubiquitin-protein aggregationwithout proteasome inhibition. Biochem Biophys Res Commun 319:1171-1180.
16. Fitzpatrick FA, Wynalda MA Albumin-catalyzed metabolism of prostaglandin D2 identification of products formed in vitro. J Biol Chem 258:11713-11718.
17. Shibata T, et al. (2002) 15-deoxy-delta 12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes. J Biol Chem 277:10459-10466.
18. Milne GL, Musiek ES, Morrow JD (2005) The cyclopentenone (A2/J2) isoprostanes - Unique, highly reactive products of arachidonate peroxidation. Antioxid Redox Sign 7:210-220.
19. Gilroy DW, et al. (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5:698-701.
20. Straus DS, Glass CK (2001) Cyclopentenone prostaglandins: New insights on biological activities and cellular targets. Med Res Rev 21:185-210.
21. Uchida K, Shibata T (2008) 15-Deoxy-Delta(12,14)-prostaglandin J2: An electrophilic trigger of cellular responses. Chem Res Toxicol 21:138-144.
22. Kim HJ, et al. (2007) 15-deoxy-Delta12,14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-alpha via covalent modification of DNA-binding domain. Cancer Res 67:2595-2602.
23. Oliva JL, et al. (2003) The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and activates H-Ras. Proc Natl Acad Sci USA 100:4772-4777.
24. Straus DS, et al. (2000) 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 97:4844-4849.
25. Perez-Sala D, Cernuda-Morollon E, Canada FJ (2003) Molecular basis for the direct inhibition of AP-1 DNA binding by 15-deoxy-Delta 12,14-prostaglandin J2. J Biol Chem 278:51251-51260.
26. Aldini G, et al. (2007) Identification of actin as a 15-deoxy-Delta12,14- prostaglandin J2 target in neuroblastoma cells: Mass spectrometric, computational, and functional approaches to investigate the effect on cytoskeletal derangement. Biochemistry 46:2707-2718.
27. Waku T, et al. (2009) Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids. J Mol Biol 385:188-199.
28. Shibata T, et al. (2003) Thioredoxin as a molecular target of cyclopentenone prostaglandins. J Biol Chem 278:26046-26054.
29. Kabuta T, et al. (2008) Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. J Biol Chem 283:23731-23738.
30. Larsen CN, Krantz BA, Wilkinson KD (1998) Substrate specificity of deubiquitinating enzymes: Ubiquitin C-terminal hydrolases. Biochemistry 37:3358-3368.
31. Osaka H, et al. (2003) Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 12:1945-1958.
32. Liu Y, et al. (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111:209-218.
33. Teismann P, et al. (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 100:5473-5478.
34. Pierre SR, Lemmens MA, Figueiredo-Pereira ME (2009) Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice. J Neuroinflamm 6:18.
35. Qin J, Clore GM, Gronenborn AM (1994) The high-resolution three-dimensional solution structures of the oxidized and reduced states of human thioredoxin. Structure 2:503-522.
36. Koharudin LMI, Furey W, Gronenborn AM (2009) A designed chimeric cyanovirin-N homolog lectin: Structure and molecular basis of sucrose binding. Proteins 77:904-915.
37. Delaglio F, et al. (1995) NMRPipe - A multidimensional spectral processing system based on Unix pipes. J Biomol Nmr 6:277-293.
38. Johnson BA, Blevins RA (1994) NMRView - A computer-program for the visualization and analysis of Nmr data. J Biomol Nmr 4:603-614.
39. Pettersen EF, et al. (2004) UCSF Chimera - A visualization system for exploratory research and analysis. J Comput Chem 25:1605-1612.